default author photo

Lai Wei

Peking University - People’s Hospital

Beijing

China

SCHOLARLY PAPERS

4

DOWNLOADS

407

TOTAL CITATIONS

2

Scholarly Papers (4)

1.

Detection of Residual HCV RNA in Patients Who Have Achieved Sustained Virological Response Is Associated with Persistent Histological Abnormality

, EBioMedicine, Volume 46, August 2019, Pages 227-235, https://doi.org/10.1016/j.ebiom.2019.07.043
Number of pages: 24 Posted: 02 May 2019
Government of the People's Republic of China - Department of Pathology and Hepatology, Peking University - Peking University Health Science Centre (PUHSC), Jilin University (JLU) - Department of Hematology, Government of the People's Republic of China - Department of Pathology and Hepatology, Government of the People's Republic of China - Department of Pathology and Hepatology, Government of the People's Republic of China - Department of Pathology and Hepatology, Government of the People's Republic of China - Department of Clinical Laboratory, Government of the People's Republic of China - Department of Pathology and Hepatology, Government of the People's Republic of China - Department of Pathology and Hepatology, Advanced Cell Diagnostics, Inc., Jilin University (JLU) - Department of Hepatology, Peking University - People’s Hospital and Government of the People's Republic of China - Department of Pathology and Hepatology
Downloads 133 (547,695)
Citation 1

Abstract:

Loading...

Occult hepatitis C; RNAscope assay; Liver fibrosis; Hepatic pathology

2.

Hepatitis C Virus Elimination is Not Attained in a Certain of Immunocompetent Patients Who Achieved Sustained Viral Response to Direct-Acting Antiviral Agents

Number of pages: 26 Posted: 28 Aug 2018
Government of the People's Republic of China - Department of Pathology and Hepatology, Peking University - Peking University Health Science Centre (PUHSC), Jilin University (JLU) - Department of Hematology, Government of the People's Republic of China - Department of Pathology and Hepatology, Government of the People's Republic of China - Department of Pathology and Hepatology, Government of the People's Republic of China - Department of Pathology and Hepatology, Government of the People's Republic of China - Department of Clinical Laboratory, Beijing 302 Military Hospital of China - Department of Pathology and Hepatology, Government of the People's Republic of China - Department of Pathology and Hepatology, Advanced Cell Diagnostics, Inc., Jilin University (JLU) - Department of Hepatology, Peking University - People’s Hospital and Government of the People's Republic of China - Department of Pathology and Hepatology
Downloads 119 (604,538)

Abstract:

Loading...

Occult Hepatitis C, Direct-Acting Antiviral Agents, Liver Fibrosis, HCV Relapse

3.

Glecaprevir/Pibrentasvir to Treat Chronic Hepatitis C Virus Infection in Asia: Two Multicentre, Phase 3 Studies – A Randomised, Double-Blind Study (VOYAGE-1) and an Open-Label, Single-Arm Study (VOYAGE-2)

Number of pages: 44 Posted: 17 Jan 2020
Peking University - People’s Hospital, Peking University - Department of Infectious Diseases, AbbVie, Capital Medical University, Pusan National University, Shanghai Jiao Tong University (SJTU) - Department of Infectious Diseases, Government of the People's Republic of China - Sixth People's Hospital of Shenyang, Seoul National University - Department of Internal Medicine, National University of Singapore (NUS), Yong Loo Lin School of Medicine, Department of Medicine, AbbVie, AbbVie, AbbVie, AbbVie, AbbVie, AbbVie, AbbVie, AbbVie, AbbVie, Capital Medical University and Southern Medical University - State Key Laboratory of Organ Failure Research
Downloads 83 (783,685)

Abstract:

Loading...

Hepatitis C; glecaprevir/pibrentasvir; sustained virological response; Asia

4.

Sofosbuvir/Velpatasvir for Treatment of Hepatitis C Virus in Asia: An Open-Label, Phase 3 Study

, Gastroenterology & Hepatology, Volume 4, Issue 2, P86-88, February 01, 2019, https://doi.org/10.1016/S2468-1253(18)30417-5
Number of pages: 127 Posted: 09 Oct 2018
Peking University - People’s Hospital, National University Hospital, Singapore - Department of Gastroenterology and Hepatology, Shanghai Jiao Tong University (SJTU) - Department of Infectious Diseases, National Hospital for Tropical Diseases, Songklanagarind Hospital, Central South University - Endocrinology Research Center, Fudan University - Shanghai Public Health Clinical Center, Guangzhou 8th People's Hospital, Sichuan University - West China Hospital, Capital Medical University - Beijing Ditan Hospital, National Hospital for Tropical Diseases, Jilin University (JLU), Jinan University, Mahidol University, China Medical University, Chiang Mai University - Maharaj Nakorn Chiang Mai Hospital, Hebei Medical University, National University of Singapore (NUS) - Singapore General Hospital, Huazhong University of Science and Technology - Department of Infectious Disease, Hospital Tengku Ampuan Afzan, Shanghai Jiao Tong University (SJTU), Shanghai Jiao Tong University (SJTU), Gilead Sciences, Inc., Gilead Sciences, Inc., Gilead Sciences, Inc., Gilead Sciences, Inc., Southeast University - The Second Hospital of Nanjing, Bach Mai Hospital, Peking University, Mahidol University, Chongqing University, Chulalongkorn University, Nanchang University, Sun Yat-sen University (SYSU), Hainan Provincial People's Hospital, 115 People's Hospital, Central South University - Second Xiangya Hospital, Central South University - Second Xiangya Hospital, Jiangsu Province People's Hospital, Guangxi Medical University, Capital Medical University, University of Malaya (UM), Southern Medical University - Nanfang Hospital and Capital Medical University
Downloads 72 (860,052)
Citation 1

Abstract:

Loading...

hepatitis C infection; NS5B polymerase inhibitor; NS5A inhibitor, Asia